Contineum Q1 net loss $16.0M, cash $190.7M; files $300M shelf & $75M ATM

Contineum Therapeutics, Inc.

Net loss of $16.0M vs $8.4M in Q1 2024; R&D expenses rose 76% to $13.7M.
Cash and equivalents of $190.7M; runway projected through 2027.
Files $300M universal shelf registration and $75M at-the-market (ATM) equity facility with Leerink Partners.
PIPE-791 Phase 1b PET topline data expected Q2 2025; Phase 2 initiation in IPF and PrMS planned H2 2025.
PIPE-307 Phase 2 VISTA RRMS topline data anticipated H2 2025; J&J Phase 2 MDD trial recruiting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.